



Theravance Biopharma to Present at Two Upcoming Investor Conferences

November 21, 2017

DUBLIN, Nov. 21, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences:

- 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 8:00 a.m. ET. The conference will be held November 28 - 29 at the Lotte New York Palace Hotel.
- Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017 at 8:45 am ET. The conference will be held November 29 - 30 at the Boston Harbor Hotel.



A live broadcast of each event will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software. Audio replays will be available for 30 days following each event.

About Theravance Biopharma

Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.

Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV[®] (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revenfenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.

In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including Trelegy Ellipta (the combination of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA[®] inhaler, previously referred to as the Closed Triple), currently approved in the US and Europe for the treatment of appropriate COPD patients and in development for the treatment of COPD in several other countries. The product is also currently in development for the treatment of asthma.

For more information, please visit www.theravance.com.

THERAVANCE[®], the Cross/Star logo, and VIBATIV[®] are registered trademarks of the Theravance Biopharma group of companies.

Contact Information:

Alexander Dobbins
Head of Investor Relations
650-808-4045
investor.relations@theravance.com

View original content with multimedia: <http://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-two-upcoming-investor-conferences-300559660.html>

SOURCE Theravance Biopharma, Inc.